Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

NCT04291664 is registered in ClinicalTrials.gov with DisperSol Technologies, LLC as lead sponsor.

NCT NCT04291664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04291664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Lead sponsor
DisperSol Technologies, LLC
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2020
Completion date
January 27, 2023
Enrollment
26 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer